The authors examined pathology from patients with renal cancer (RCC) treated with IL-2 to
determine response rates for clear cell and variant RCC and to identify histologic features
that predict response. Pathology specimens were reviewed by a single pathologist who was
blinded to both the prior pathology interpretation and the therapeutic response. Findings
were correlated with response to IL-2 therapy. Evaluable pathology specimens were
obtained from 231 patients. Of 163 primary RCCs, the response rate was 21%(30/146) for …